May 29, 2020: The Week in Cancer News
A study shows that a more tolerable, dose-adjusted chemotherapy regimen can effectively treat a rare lymphoma, and more news of the week from Cancer Today.
Progress Against Cancer
A study shows that a more tolerable, dose-adjusted chemotherapy regimen can effectively treat a rare lymphoma, and more news of the week from Cancer Today.
The days are getting longer and warmer, and visions of beach trips, cookouts, and picnics occupy our minds. While this year’s summer will likely look different due to the ongoing COVID-19 pandemic, months of staying inside may make the desire to head outside even stronger.
Signaling pathways that regulate cellular proliferation are commonly mutated in cancer cells, leading to unrestrained cellular division and tumor growth. Therefore, insight into the regulation of these signaling pathways is critical to the development of novel therapeutics. Mutations in the RAS...
Metastatic prostate cancer incidence rose after changes to prostate cancer screening guidelines.
A study indicates that children with cancer are not at increased risks of severe cases of COVID-19, and more news of the week from Cancer Today.
In the United States, nearly 24,000 people are estimated to receive a brain or nervous system cancer diagnosis in 2020. Even though these cancers represent only about 1 percent of all new cancer cases, brain and other nervous system cancers are the ninth leading cause of cancer-related mortality.
Bladder cancer is a common malignancy originating in the bladder, a hollow organ located in the abdomen that stores urine. It is the sixth most prevalent cancer in the United States and has a high rate of recurrence. Over 90 percent of bladder cancers are urothelial carcinomas, which originate in the innermost tissue layer of the bladder lining.
A study finds that the rate of death from opioids was 10 times lower in cancer patients than in the general population between 2006 and 2016
Over the past decade, immune checkpoint inhibitors have transformed cancer care for a variety of tumor types. This form of immunotherapy can lead to long-lasting responses in some patients; however, most patients’ cancers do not respond to this therapy, and those that initially respond may develop resistance.
Researchers present new data on cancer biology, treatment, screening and risk reduction at the AACR Virtual Annual Meeting I.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More